Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.65 |
| ▸ | MGLL | Q99685 | 3/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20983861 | 0.99 | ABHD6 (0.66) | ABHD6MGLLHRH3KDM4EFLT3 | |
| SCHEMBL20983871 | 0.92 | ABHD6 (0.68) | ABHD6MGLLHRH3KDM4E | |
| SCHEMBL20983857 | 0.83 | ABHD6 (0.60) | ABHD6MGLL | |
| SCHEMBL20983786 | 0.81 | ABHD6 (0.62) | ABHD6MGLLKDM4EFLT3POLB | |
| SCHEMBL20983831 | 0.80 | ABHD6 (0.61) | ABHD6MGLL | |
| SCHEMBL20983840 | 0.79 | ABHD6 (0.63) | ABHD6MGLL | |
| SCHEMBL20983800 | 0.79 | ABHD6 (1.00) | ABHD6MGLLHRH3 | |
| SCHEMBL20983863 | 0.78 | ABHD6 (1.00) | ABHD6MGLLHRH3 | |
| SCHEMBL20983760 | 0.78 | ABHD6 (0.53) | ABHD6MGLLKDM4E | |
| SCHEMBL20983806 | 0.77 | ABHD6 (0.59) | ABHD6MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | MAKSCIENTIFIC, LLC | 2019-05-23 | — | — | US | claimed |
| US-10662159-B2 | ABHD6 and dual ABHD6/MGL inhibitors and their uses | MAKSCIENTIFIC, LLC (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | MAKSCIENTIFIC, LLC | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662159-B2 | ABHD6 and dual ABHD6/MGL inhibitors and their uses | ABHD6, FAAH, FAAH2 | ABHD6 1/4885MGLL 5/4885HRH3 231/4885 |
| US-20190152917-A1 | ABHD6 AND DUAL ABHD6/MGL INHIBITORS AND THEIR USES | ABHD6, FAAH, FAAH2 | ABHD6 1/4885MGLL 5/4885HRH3 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.